MiNA Therapeutics
Oct 18, 2018
Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug
Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis’ eye for USD 12 million. Endocyte was in the stagnation when it held its recovery h...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
